10-Q: Zenas BioPharma Reports First Quarter 2025 Financial Results, Driven by Collaboration Revenue

Zenas BioPharma reports a net loss of $33.6 million for Q1 2025, but recognizes $10 million in license and collaboration revenue.

Summary

• Zenas BioPharma, a clinical-stage biopharmaceutical company, filed its Form 10-Q for the quarter ended March 31, 2025.
• The company reported a net loss of $33.6 million for the quarter, compared to a net loss of $27.8 million for the same period in 2024.
• Zenas BioPharma recognized $10.0 million in license and collaboration revenue during the quarter, stemming from the Zai License Agreement.
• Research and development expenses increased to $34.9 million from $22.6 million in the prior year, driven by obexelimab development costs.
• General and administrative expenses also increased to $12.4 million from $4.9 million, primarily due to personnel costs and public company expenses.
• As of March 31, 2025, the company's cash, cash equivalents, and investments totaled $314.2 million.
• Zenas BioPharma believes its current resources will fund operations into the fourth quarter of 2026.
• The company is developing obexelimab for IgG4-RD, relapsing multiple sclerosis (RMS), and systemic lupus erythematosus (SLE).
• Zenas BioPharma is also advancing ZB002 and ZB004, while ZB001 has been sublicensed to a partner in China.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company reported a net loss, it also recognized revenue and has a cash runway into the fourth quarter of 2026. The company faces risks associated with clinical development and regulatory approval, but it is also pursuing multiple product candidates and collaborations.

Positives

• The company recognized $10.0 million in license and collaboration revenue due to the Zai License Agreement.
• Existing resources are expected to fund operations into the fourth quarter of 2026.

Negatives

• Zenas BioPharma reported a net loss of $33.6 million for Q1 2025.
• Research and development expenses increased to $34.9 million.
• General and administrative expenses also increased to $12.4 million.

Risks

• The company is a clinical-stage biopharma with a limited operating history and no products approved for commercial sale.
• Zenas BioPharma anticipates incurring substantial and increasing losses for the foreseeable future.
• The company will require substantial additional financing to achieve its goals.
• Clinical development is lengthy and expensive, characterized by uncertain outcomes.
• Delays or difficulties in patient enrollment and dosing in clinical trials could delay or prevent regulatory approvals.
• Significant adverse events or undesirable side effects caused by product candidates may delay or prevent regulatory approval.
• The company faces potential competition from different sources with substantial investments in novel treatments.
• The company may not realize the benefits of current or future collaborations or licensing arrangements.
• The company is dependent on the services of its senior management and other clinical and scientific personnel.
• The manufacturing of product candidates is complex, and third-party manufacturers may encounter difficulties in production.
• The company's rights to develop and commercialize product candidates are subject to the terms and conditions of licenses granted by others.
• The operations of suppliers, many of which are located outside of the U.S., are subject to additional risks that are beyond the company's control.
• An active and liquid trading market for the company's common stock may not be sustained.
• The market price of the company's common stock may be volatile, which could result in substantial losses for investors.

Future Outlook

Zenas BioPharma expects to continue to incur significant and increasing losses for the foreseeable future and believes that its existing cash, cash equivalents and investments will be sufficient to fund its operations and capital expenditure requirements into the fourth quarter of 2026.

Management Comments

• Management expects operating losses and negative operating cash flows to continue for the foreseeable future.
• The Company expects that its existing cash, cash equivalents and investments of $314.2 million as of March 31, 2025 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date this Form 10-Q is filed.
• The Company will need additional financing to support its continuing operations and to pursue its growth strategy.

Industry Context

Zenas BioPharma operates in the competitive biopharmaceutical industry, focusing on immunology and inflammation (I&I) therapies. The company faces competition from established pharmaceutical and biotechnology companies, as well as academic and research institutions. The success of Zenas BioPharma depends on its ability to develop and commercialize innovative therapies that can compete with existing treatments and address unmet medical needs.

Comparison to Industry Standards

• Comparing Zenas BioPharma's financial performance to industry standards requires considering its stage of development and focus area.
• As a clinical-stage company, Zenas BioPharma's primary expenses are R&D, which are typical for companies in this phase.
• Comparable companies include other clinical-stage biopharmaceutical firms such as Viridian Therapeutics, Inc. and Xencor, Inc., which are also focused on immunology and inflammation.
• Viridian Therapeutics, Inc. reported R&D expenses of $43.4 million for the three months ended March 31, 2024, while Xencor, Inc. reported R&D expenses of $78.4 million for the same period.
• Zenas BioPharma's R&D expenses of $34.9 million are within the range of these comparable companies, but lower than Xencor, reflecting its smaller scale.
• The $10 million in license and collaboration revenue is a positive sign, but the company will need to continue to secure partnerships to generate revenue.
• The cash runway into the fourth quarter of 2026 is also a positive, but the company will need to raise additional capital to continue its development programs.

Legal Proceedings

• In April 2025, a putative securities class action was filed against us and certain of our directors and officers, as well as the underwriters in our IPO.
• The action, purportedly brought on behalf of a putative class of purchasers of our common stock in, or traceable to, our IPO, asserts claims under Sections 11, 12, and 15 of the Securities Act of 1933, as amended.
• The action seeks compensatory damages, attorneys fees and costs, and any other relief that the court determines is just and proper.

Related Party Transactions

• The Company has obtained exclusive, worldwide licenses from Xencor to research, develop, manufacture, market and sell three antibody product candidates pursuant to two license agreements.
• The Company has obtained a license from Viridian to research, develop, manufacture, market and sell an antibody product candidate in China.
• The Company has granted a sublicense to Zai to develop, manufacture and commercialize ZB001 and related programs in greater China.

Stakeholder Impact

• Shareholders: The company's financial performance and future prospects will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is critical to its success.
• Patients: The company's development of new therapies has the potential to improve patient outcomes.
• Suppliers: The company's relationships with suppliers are important for ensuring a reliable supply of materials.
• Creditors: The company's ability to repay its debts depends on its financial performance.

Next Steps

• Continue clinical development of obexelimab and other programs.
• Advance obexelimab program and other product candidates through preclinical development and clinical trials.
• Identify additional product candidates and acquire rights from third parties through licenses or acquisitions.
• Seek marketing regulatory approvals for current or any future product candidates that successfully complete clinical trials.
• Commercialize current or any future product candidates, if approved.
• Continue to develop, maintain and defend intellectual property portfolio.
• Seek to attract, hire and retain qualified clinical, scientific, operations and management personnel.

Key Dates

Keywords

Zenas BioPharma, obexelimab, clinical trials, biopharmaceutical, immunology, inflammation, ZB001, ZB002, ZB004, ZB005, license agreement, collaboration, financial results, net loss, revenue, research and development, regulatory approval, BMS, Xencor, Zai Lab